Lv2
160 积分 2022-09-14 加入
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09
1个月前
已完结
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05
1个月前
已关闭
7O Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07
1个月前
已关闭
药品微生物数据偏差调查规范和研究概述
3个月前
已完结
Development of Regulation and Policy for Cell Therapies in China
3个月前
已完结
Metastatic site radiation therapy for Ewing sarcoma and rhabdomyosarcoma: Consensus guidelines from the National Pediatric Cancer Foundation
8个月前
已关闭
The 2024 ILTS-ILCA consensus recommendations for liver transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
8个月前
已完结
皖公网安备34019202002308
